Gotham Asset Management LLC Increases Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Gotham Asset Management LLC increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 25.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 29,351 shares of the medical research company’s stock after acquiring an additional 5,944 shares during the quarter. Gotham Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $15,269,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Full Sail Capital LLC increased its position in shares of Thermo Fisher Scientific by 1.7% during the 4th quarter. Full Sail Capital LLC now owns 2,169 shares of the medical research company’s stock valued at $1,128,000 after purchasing an additional 37 shares during the last quarter. Ellevest Inc. grew its position in shares of Thermo Fisher Scientific by 5.4% during the 4th quarter. Ellevest Inc. now owns 1,357 shares of the medical research company’s stock valued at $706,000 after acquiring an additional 70 shares during the period. Ethic Inc. raised its holdings in Thermo Fisher Scientific by 13.7% in the 4th quarter. Ethic Inc. now owns 42,002 shares of the medical research company’s stock worth $21,851,000 after purchasing an additional 5,066 shares during the period. Farallon Capital Management LLC lifted its position in Thermo Fisher Scientific by 73.8% during the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company’s stock valued at $641,577,000 after purchasing an additional 523,800 shares in the last quarter. Finally, First Manhattan CO. LLC. increased its position in Thermo Fisher Scientific by 0.6% in the fourth quarter. First Manhattan CO. LLC. now owns 891,321 shares of the medical research company’s stock worth $464,010,000 after buying an additional 4,991 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. This trade represents a 1.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 14,075 shares of company stock valued at $7,305,942 in the last quarter. 0.33% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TMO. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 23rd. Scotiabank reduced their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a research note on Friday, April 25th. Barclays dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Raymond James restated an “outperform” rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Finally, Robert W. Baird cut their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $607.43.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $402.93 on Friday. The company has a market cap of $152.10 billion, a P/E ratio of 24.38, a P/E/G ratio of 2.99 and a beta of 0.82. The business’s 50 day moving average price is $464.67 and its 200-day moving average price is $514.85. Thermo Fisher Scientific Inc. has a fifty-two week low of $401.75 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same quarter last year, the business earned $5.11 EPS. The business’s revenue was up .2% on a year-over-year basis. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.